

To,
The Corporate Relationship Department
BSE Limited
Phiroze Jeejeebhoy Tower
Dalal Street, Fort
Mumbai-Maharashtra 400001

Date: 14th November, 2024

Subject: Submission of Unaudited Financial Results along with Limited Review Report for the Quarter and Half Year ended 30th September, 2024

Ref: Scrip Code: 526546, ISIN: INE493D01013.

Dear Sir/Madam,

Pursuant to Regulation 30 & 33 of the SEBT (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the following:

1. Considered and approved **Unaudited Financial Results** along with Limited Review Reports for the Quarter and Half Year ended on 30th September, 2024.

The aforesaid results are duly approved by the Audit Committee and Board of Directors in their respective meetings held on Thursday, 14th November, 2024.

You are requested to take the same on your record.

Thanking You

Yours faithfully

For CHOKSI LABORATORIES LIMITED

**PRAKHAR DUBEY
COMPANY SECRETARY &
COMPLIANCE OFFICER**

PRATEEK JAIN & CO.

CHARTERED ACCOUNTANTS

212, SHALIMAR CORPORATE CENTRE, 8-B, SOUTH TUKOGANJ,
INDORE (M.P.) 452001

PH. 9827013187, 731-3590283

E-MAIL: caofficepjain@gmail.com



Independent Auditor's Review Report on the unaudited Quarterly and Year to date Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors
Choksi Laboratories Limited
Indore (M.P.) - 452001

We have reviewed the accompanying statement of unaudited financial results of **CHOKSI LABORATORIES LIMITED** ("the Company") for the quarter ended **September 30, 2024 and year to date from April 01, 2024 to September 30, 2024** ("the statement") attached herewith, being submitted by the Company pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ("the listing regulations").

This statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 (as amended) and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE 2410) "Review of Interim Financial Information Performed by Independent auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



PRATEEK JAIN & CO.

CHARTERED ACCOUNTANTS

212, SHALIMAR CORPORATE CENTRE, 8-B, SOUTH TUKOGANJ,

INDORE (M.P.) 452001

PH. 9827013187, 731-3590283

E-MAIL: caofficejain@gmail.com



Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in all material respect in accordance with the applicable Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other recognized accounting practices generally accepted in India, has not disclosed the information required to be disclosed in terms of Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR PRATEEK JAIN AND CO.
CHARTERED ACCOUNTANTS
FRN-009494C



PRATEEK JAIN
PROPRIETOR
M.NO.079214

Date: 14th November, 2024

Place: Indore

UDIN: 24079214BKGYXQ2924

CHOKSI LABORATORIES LIMITED

Statement of Standalone Unaudited financial Results for the Quarter and 6 Months Ended on 30th September 2024

As per Schedule III of the Companies Act, 2013

(₹ In Lakhs)

Sl. No.	Particulars	Quarter Ended on			Half Year Ended on		Year Ended
		3 Months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to Date figures for the current period	Year to Date figures for the corresponding 6 month ended in the previous year	Year to date figures for current period ended
		30.09.2024 (Unaudited)	30.06.2024 (Unaudited)	30.09.2023 (Unaudited)	30.09.2024 (Unaudited)	30.09.2023 (Unaudited)	31.03.2024 (Audited)
I	Revenue from Operation	926.22	1073.64	795.05	1999.86	1678.00	3669.51
II	Other Income	0.90	0.54	4.64	1.44	9.69	16.41
III	Total Income (I+II)	927.12	1074.18	799.69	2001.30	1687.69	3685.92
IV	Expenses						
	(a) Cost of materials consumed	62.09	87.63	42.59	149.72	102.39	255.94
	(b) Employee benefits expense	412.93	393.86	353.01	806.79	705.59	1454.88
	(c) Finance Cost	65.74	71.89	74.34	137.63	156.25	300.53
	(d) Depreciation and amortisation expense	161.30	150.38	140.83	311.68	279.60	571.35
	(e) Laboratories Maintenance Expenses	92.75	115.76	74.74	208.51	157.39	346.57
	(f) Power & Fuel Charges	26.07	26.83	21.10	52.90	44.50	83.80
	(g) Other expenses	96.59	166.33	92.33	262.92	218.93	506.53
	Total expenses	917.47	1012.68	798.94	1930.15	1664.65	3519.60
V	Profit / (Loss) before exceptional items and tax (III-IV)	9.65	61.50	0.75	71.15	23.04	166.32
VI	Exceptional items	-	-	-	-	-	-
VII	Profit / (Loss) before tax (V-VI)	9.65	61.50	0.75	71.15	23.04	166.32
VIII	Tax Expenses						
	(a) Current Tax	3.37	10.51	1.71	13.88	5.20	27.64
	(b) Income Tax Earlier Year	0.00	-	1.49	0.00	2.15	6.43
	(c) Mat Credit Entitlement	(3.37)	(10.51)	(1.71)	(13.88)	(5.20)	(27.64)
	(d) Deferred Tax	2.10	19.43	(1.42)	21.53	(15.58)	48.91
IX	Net Profit / (Loss) for the period from continuing operations (VII-VIII)	7.55	42.07	0.68	49.62	36.47	110.98
X	Other Comprehensive Income						
	(a) (i) Items that will not be reclassified to profit & loss	16.61	0.61	13.79	17.22	13.90	2.43
	(ii) Income tax relating to items that will not be reclassified to profit & loss	(4.32)	(0.16)	(3.58)	(4.48)	(3.61)	(0.63)
	(b) (i) Items that will be re-classified to profit & loss	16.71	7.35	-	24.06	-	(3.46)
	(ii) Income tax relating to items that will be reclassified to profit & loss	(4.35)	(1.91)	-	(6.26)	-	0.90
XI	Total Comprehensive Income (IX+X)	32.20	47.96	10.89	80.16	46.76	110.22
XII	Detail of equity share capital						
	(a) Paid-up equity share capital	696.52	696.52	696.52	696.52	696.52	696.52
	(b) Face value of equity share capital (in Rs.)	10.00	10.00	10.00	10.00	10.00	10.00
XIII	Earnings per equity share (for continuing operations)						
	(a) Basic	0.11	0.60	0.01	0.71	0.52	1.59
	(b) Diluted	0.11	0.60	0.01	0.71	0.52	1.59
XIV	Earnings per equity share (for Dis-continuing operations)						
	(a) Basic	-	-	-	-	-	-
	(b) Diluted	-	-	-	-	-	-
XV	Earnings per equity share (for Dis-continued and continuing operations)						
	(a) Basic	0.11	0.60	0.01	0.71	0.52	1.59
	(b) Diluted	0.11	0.60	0.01	0.71	0.52	1.59

Cont..

For Choksi Laboratories Ltd.

[Signature]
Director

Statement of Assets and Liabilities as on 30th September '2024

(₹ In Lakhs)

Sr No	Particulars	As at 30.09.2024 Unaudited	As at 31.03.2024 Audited
	ASSETS		
1	Non- Current Assets		
	a) Property, plant and equipment	4599.32	4216.56
	b) Capital work-in-progress	0.00	267.89
	c) Right of use Asset	100.21	122.43
	d) Intangible assets	33.95	4.41
	e) Intangible assets under development	-	31.57
	f) Financial assets		
	i) Investments	-	-
	ii) Loans	-	-
	iii) Other financial assets	81.80	53.00
	g) Deferred tax Asset (Net)	6.91	39.18
	h) Other non current assets	2.80	3.35
	Total non-current assets	4824.99	4738.39
2	Current assets		
	a) Inventories	65.38	36.37
	b) Financial assets		
	i) Investments	-	-
	ii) Trade receivables	1051.31	1039.32
	iii) Cash and cash equivalents	21.72	65.69
	iv) Bank Balance other than (iii) above	-	-
	v) Loans	-	-
	vi) Other financial assets	9.94	50.72
	c) Current Tax Assets (Net)	290.22	208.05
	c) Other current assets	137.00	56.69
	Total current assets	1575.57	1456.84
	TOTAL ASSETS	6400.56	6195.23
	EQUITY AND LIABILITIES		
1	Equity		
	a) Equity share capital	696.53	696.53
	b) Other equity	1604.68	1524.52
	Total Equity	2301.21	2221.05
2	Liabilities		
	i) Non-current liabilities		
	a) Financial liabilities		
	i) Long Term Borrowings	1844.20	1799.66
	ii) Lease Liabilities	87.31	108.16
	iii) Other Non Current Financial Liabilities	-	-
	b) Long Term Provision	176.20	181.60
	c) Deferred tax liabilities (Net)	-	-
	Total non-current liabilities	2107.71	2089.42
	ii) Current liabilities		
	a) Financial liabilities		
	i) Short Term Borrowings	1021.85	1127.69
	ii) Lease Liabilities	47.04	51.75
	iii) Trade payables (MSE)	29.53	50.52
	iv) Trade payables (Other than MSE)	508.06	342.58
	v) Other Current Financial Liabilities	297.42	235.13
	b) Other current liabilities	80.03	76.99
	c) Short Term Provisions	7.71	0.10
	Total Current liabilities	1991.64	1884.76
	Total Liabilities	4099.35	3974.18
	TOTAL EQUITY AND LIABILITIES	6400.56	6195.23

Cont..

For Choksi Laboratories Ltd.


Director

Corporate Office & Central Laboratory :Survey No. 9/1., Balaji Tulsiyana Industrial Park,
Kumedi, Off. M.R. 10 Toll Naka, Indore – 452010, M.P. (India)

Tel. +91 731 3501112 (60 Lines)

Email : bd@choksilab.com

Website : www.choksilab.com

CASH FLOW STATEMENT FOR THE HALF YEAR ENDED YEAR ENDED 30th Sep 2024

(₹ In Lakhs)

Particulars	For the Half Year ended 30th September 2024	For the Half Year ended 30th September 2023
Cash flow from operating activities		
Profit before income tax	71.15	23.04
Adjustments for:		
Depreciation and amortisation expense	311.67	279.60
Loss/(Gain) on disposal of property, plant & equipment	0.02	-
Provision/Write off Doubtful Trade Receivables	21.07	(10.79)
Interest Received	(1.41)	(9.69)
Foreign Exchange Gain	0.00	0.00
Finance costs	137.63	156.25
Operating Profit before working Capital Changes	540.13	438.41
Adjustments for :		
(Increase)/Decrease in trade receivables	(33.05)	69.53
(Increase) in inventories	(29.01)	(41.78)
Increase in trade payables	144.50	237.38
(Increase) in other financial assets	11.97	4.88
(Increase)/decrease in other non-current assets	0.55	(2.10)
(Increase)/decrease in other current assets	(80.31)	(74.49)
Increase/(decrease) in provisions	7.61	(23.47)
Increase / (decrease) in employee benefit obligations	11.82	16.15
Increase/(decrease) in Current Financial Liabilities	62.28	-
Increase in other current liabilities	3.04	(27.75)
Cash generated from operations	639.53	596.76
Income taxes paid/(refunds) Net	80.00	100.19
Net cash inflow from operating activities	559.53	496.57
Cash flows from investing activities		
Payments for property, plant and equipment	(316.50)	(117.81)
Payments for Capital Work In Progress	(83.11)	(214.05)
Payments for Intangible Assets	(1.75)	(4.78)
Payments for Intangible Assets Under development	(1.05)	-
Proceeds from sale of property, plant & equipment	0.10	6.63
Proceeds from Maturity of Fixed Deposits	0.00	19.25
Interest received	1.41	9.69
Net cash outflow from investing activities	(400.90)	(301.07)
Cash flows from financing activities		
Proceeds from Long term borrowings	212.54	2890.21
Repayment of Long term borrowing	(286.21)	(2444.99)
Short term borrowings	34.27	430.94
Proceeds from Government Grant in respect of Tangible Assets	-	-
Finance Cost (Interest paid)	(137.63)	(156.25)
Payments of Lease Obligations	(25.57)	(23.50)
Net cash inflow (outflow) from financing activities	(202.60)	696.41
Net increase (decrease) in cash and cash equivalents	(43.97)	891.91
Cash and cash equivalents at the beginning of the financial year	65.69	33.75
Cash and cash equivalents at end of the year	21.72	925.66

1

Components of Cash and cash equivalents :		
Balances with Banks		
in Current accounts	9.88	918.92
Cash in Hand	11.84	6.74
Cash and Cash equivalents in cash flow statement	21.72	925.66

1. The above Cash Flow Statement has been prepared under the Indirect Method as set out in Ind AS 7 Statement of Cash Flow.

2. Figures for the Previous Year have been re-arranged and re-grouped wherever necessary to confirm with the Current year classification.

Cont.

For Choksi Laboratories Ltd.



Director

Corporate Office & Central Laboratory :

Survey No. 9/1., Balaji Tulsiyana Industrial Park,
Kumedi, Off. M.R. 10 Toll Naka, Indore – 452010, M.P. (India)
Tel. +91 731 3501112 (60 Lines)
Email : bd@choksilab.com
Website : www.choksilab.com

Notes to the results :

- 1 These results have been prepared as per Regulation 33 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 and in accordance with the Indian Accounting Standards (Ind AS) notified under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules 2015 as amended and other accounting principles generally accepted in India.
- 2 The figures for the quarter and half year ended on 30th September, 2024 are the balancing figures between unaudited figures in respect of the half year ended on September 30, 2024 and the published unaudited figures for the quarter ended on June 30, 2024.
- 3 The above Financial Results for the quarter and half Year ended on 30th September 2024 have been reviewed by the Audit Committee and approved & taken on record by the Board at their Board meeting held on Thursday, 14th November 2024.
- 4 Depreciation on fixed assets is provided on straight line method as per the estimated remaining useful lives of assets.
- 5 The Company has identified "Analysis and Testing" as the single operating segment for the continued operations in the financial statements as per Ind AS 108 "Operating Segments".
- 6 Revenue from Operations is shown exclusive of GST
- 7 "Other Income" for the quarter and half year ended on 30 September 2024 includes :-
Interest Income ₹ 1.41 Lakhs & Forex Gain ₹ 0.03 Lakhs.
- 8 Figures for the previous periods have been regrouped, wherever necessary and minus figures are shown in brackets.
- 9 Earnings per share amount is shown in Rupees (₹).
- 10 For any queries email at compliance_officer@choksilab.com

Date: 14th November 2024
Place: Indore

For and on behalf of the Board of Directors of
CHOKSI LABORATORIES LIMITED


Sumit Choksi
Managing Director
DIN 00155078

